De Jong, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of enzastaurin + fulvestrant versus Fulvestrant in

        Z

AnnOncol2012; 23: ix124.  



Studied treatment
Control treatment



Patients
Group sizes-9 / -9



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI objective response - -9 - -9 no data progression-free survival (PFS) - -9 - -9 no data overall survival (OS) - -9 - -9 no data treatment-related deaths - -9 - -9 no data hypertension (grade 3) - -9 - -9 no data arterial thromboembolic event - -9 - -9 no data gastrointestinal perforation (grade 3) - -9 - -9 no data left ventricular systolic dysfunction (grade 2 or 3) - -9 - -9 no data high-grade congestive heart failure - -9 - -9 no data serious adverse events - -9 - -9 no data arterial/venous thromboembolism (grade 3) - -9 - -9 no data pulmonary embolism (grade 3) - -9 - -9 no data bleeding (grade 3) - -9 - -9 no data cardiomyopathy (grade 3) - -9 - -9 no data permanent discontinuation - -9 - -9 no data adverse events grade 3 - -9 - -9 no data venous thromboembolic event (grade 3) - -9 - -9 no data proteinuria (grade 3) - -9 - -9 no data wound-healing complications (grade 3) - -9 - -9 no data0,22,01,0

De Jong RS, Sonke GS, Maass N et al. Fulvestrant (FUL)plus enzastaurin (ENZA) vs FUL plus placebo (PBO) inaromatase inhibitor (AI)-resistant metastatic breast cancer(MBC): a randomized, double-blind, phase 2 trial. AnnOncol2012; 23: ix124.     [PMID: ]   link to pdf   add to Mendeley  



Registering number (see trial on clinicaltrials.gov)
Code Name